Monoclonal antibody-based therapy for renal cell carcinoma.
Monoclonal antibody G250 treatment may have a role in the management of metastatic RCC; however, particular subgroups who are more prone to benefit from this treatment must be delineated. High-risk patients may benefit from adjuvant treatment with this nontoxic treatment modality. Large cohort studies are needed to investigate this possibility.
Oosterwijk
Egbert
E
Nijmegen Center for Molecular Life Sciences, 190 Experimental Urology, University Medical Center Nijmegen, Geert Grooteplein Zuid 28, 6525 Nijmegen, The Netherlands. e.oosterwijk@uro.umcn.nl
Divgi
Chaitanya R
CR
Brouwers
Adrienne
A
Boerman
Otto C
OC
Larson
Steven M
SM
Mulders
Peter
P
Old
Lloyd J
LJ
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology*; D002292:Carcinoma, Renal Cell / Q000628:therapy*; D006801:Humans; D007680:Kidney Neoplasms / Q000628:therapy*
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; C400566:antigen G250